Harrow Reports First Quarter Results, Points to High Demand for Vevye

Published on May 12, 2026
NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America for both the front and back of the eye, has announced results for the first quarter that ended March 31, 2026. The company reported revenue of $44.2 million for the quarter, including a non-recurring gross-to-net revenue adjustment connected to new commercial coverage for Vevye that lowered revenue by approximately $8 million. A prescription drop, Vevye (cyclosporine ophthalmic solution) 0.1% is used to treat the signs and symptoms of dry eye disease.
Continue reading on website
Other news

Safilo Group Inks Deal to Acquire SPY+ and Serengeti

May 12, 2026
PADUA, Italy—Safilo Group announced yesterday that it has signed a share and asset purchase agreement (SAPA) with Bollé Brands for the acquisition of SPY+ and Serengeti. The news comes on the heels of an announcement from Safilo Group in April that it had signed an exclusivity agreement with Bollé Brands aimed at the acquisition of the two U.S. brands, which operate in the sports/outdoor and high-

Physician-scientist and innovator Daniel Kraft to keynote Optometry’s Meeting®

May 12, 2026
Hear Kraft’s keynote on the future of health, medicine and technology during the AOA Experience: Opening Session, supported by Johnson & Johnson Vision, on June 17.